Max is a Partner in Trinity’s Evidence, Value, Access and Pricing (EVAP) practice. His experience as a global life sciences strategy consultant spans all stages of product development and a wide range of therapeutic areas, including oncology, inflammatory conditions, rare diseases and cell and gene therapies.

Over the last decade, Max’s work has spanned a range of strategic issues related to pricing, access, value and policy with a focus in the U.S., Europe, Japan and other global markets. Max is devoted to delivering innovative and impactful commercial strategy recommendations to biopharmaceutical manufacturers working to navigate the evolving payer marketplace and policy environment.

Max previously worked in the strategy consulting division of Leerink Partners and holds a BS in Biomedical Engineering from Johns Hopkins University. Select prior work covering the IRA can be found here and here.